Liquid chromatography-electrospray mass spectrometry determination of ibogaine and noribogaine in human plasma and whole blood. Application to a poisoning involving Tabernanthe iboga root

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 843, Issue 2, 2006, Pages 131-141

  Kontrimavičiute, Violeta ^a,b   Breton, Hélène ^c,d   Mathieu, Olivier ^c   Mathieu Daudé, Jean Claude ^c   Bressolle, Françoise M M ^a  

^a UNIV MONTPELLIER   (France)

^b KAUNAS UNIVERSITY OF MEDICINE   (Lithuania)

^c LAPEYRONIE HOSPITAL   (France)

^d HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

Forensic samples; Ibogaine; LC ESI MS; Noribogaine; Plasma and whole blood; Quantitation

Indexed keywords

DATA ACQUISITION; DRUG PRODUCTS; EXTRACTION; IONIZATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MICROSCOPIC EXAMINATION;

FORENSIC SAMPLES; IBOGAINE; NORIBOGAINE; QUANTITATION; SOLID PHASE EXTRACTION;

BLOOD;

ACETONITRILE; AMMONIUM FORMATE; FLUORESCEIN; IBOGAINE; NORIBOGAINE; TRIMETHYLAMINE;

ADULT; ARTICLE; BLOOD; CASE REPORT; CONCENTRATION (PARAMETERS); ELECTROSPRAY MASS SPECTROMETRY; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MEDICINAL PLANT; PLANT ROOT; PLASMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SOLID PHASE EXTRACTION; TABERNANTHE IBOGA;

CHROMATOGRAPHY, LIQUID; DRUG STABILITY; FORENSIC TOXICOLOGY; HUMANS; IBOGAINE; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TABERNAEMONTANA;

TABERNANTHE IBOGA;

EID: 33750309624     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2006.05.035     Document Type: Article

References (38)

1. Zubaran C. CNS Drug Rev. 6 (2000) 219
2. Naranjo C. Clin. Toxicol. 2 (1969) 209
3. Goutarel R., Gollnhoffer O., and Sillans R. Psychedelic Monogr. Essays 6 (1993) 71
4. Popik P., and Skolnick P. In: Cordell G.A. (Ed). The Alkaloids (1999), Academic Press, San Diego 197
5. Glick S.D., Kuehne M.E., Raucci J., Wilson T.E., Larson E., Keller R.W., and Carlson J.N. Brain Res. 657 (1994) 14
6. Glick S.D., Pearl S.M., Cai J., and Maisonneuve I.M. Brain Res. 713 (1996) 294
7. Glick S.D., and Maisonneuve I.M. Ann. N.Y. Acad. Sci. 844 (1998) 214
8. Glick S.D., and Maisonneuve I.M. Ann. N.Y. Acad. Sci. 909 (2000) 88
9. Mash D.C., Kovera C.A., Buck B.E., Norenberg M.D., Shapshak P., Hearn W.L., and Sanchez-Ramos J. Ann. N.Y. Acad. Sci. 844 (1998) 274
10. Mash D.C., Kovera C.A., Pablo J., Tyndale R.F., Ervin F.D., Williams I.C., Singleton E.G., and Mayor M. Ann. N.Y. Acad. Sci. 914 (2000) 394
11. Mash D.C., Kovera C.A., Pablo J., Tyndale R., Ervin F.R., Kamlet J.D., and Hearn W.L. Alkaloids 56 (2001) 155
12. Maisonneuve I.M., Visker K.E., Mann G.L., Bandarage U.K., Kuehne M.E., and Glick S.D. Eur. J. Pharmacol. 336 (1997) 123
13. Wei D., Maisonneuve I.M., Kuehne M.E., and Glick S.D. Brain Res. 800 (1998) 260
14. Cappendijk S.L.T., and Dzoljic M.R. Eur. J. Pharmacol. 241 (1993) 261
15. Rezvani A.H., Overstreet D.H., and Lee Y.W. Pharmacol. Biochem. Behav. 52 (1995) 615
16. Baumann M.H., Pablo J., Ali S.F., Rothman R.B., and Mash D.C. Alkaloids 56 (2001) 79
17. Baumann M.H., Rothman R.B., Pablo J., and Mash D.C. J. Pharmacol. Exp. Ther. 297 (2001) 531
18. Baumann M.H., Pablo J.P., Ali S.F., Rothman R.B., and Mash D.C. Ann. N.Y. Acad. Sci. 914 (2000) 354
19. Obach R.S., Pablo J.P., and Mash D.C. Drug Metab. Dispos. 26 (1998) 764
20. Dhahir H.I., Jain N.C., and Thornton J.I. J. Forensic Sci. Soc. 12 (1972) 309
21. Bertol E., Mari F., and Froldi R. J. Chromatogr. 117 (1976) 239
22. Dagnino D., Schripsema J., Peltenburg A., Verpoorte R., and Teunis K. J. Nat. Prod. 54 (1991) 1558
23. Cartoni G.P., and Giarusso A. J. Chromatogr. 71 (1972) 154
24. Gallagher C.A., Hough L.B., Keefner S.M., Seyed-Mozaffari A., Archer S., and Glick S.D. Biochem. Pharmacol. 49 (1995) 73
25. Ley F.R., Jeffcoat A.R., and Thomas B.F. J. Chromatogr. A. 723 (1996) 101
26. Hearn W.L., Pablo J., Hime G.W., and Mash D.C. J. Anal. Toxicol. 19 (1995) 427
27. Alburges M.E., Foltz R.L., and Moody D.E. J. Anal. Toxicol. 19 (1995) 381
28. Bogusz M.J., Maier R.D., Kruger K.D., and Kohls U. J. Anal. Toxicol. 22 (1998) 549
29. Kontrimavičiūtė V., Larroque M., Briedis V., Margout D., and Bressolle F. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 822 (2005) 285
30. US Food and Drug Administration, Guidance for industry, Bioanalytical Method Validation, May 2001. http://www.fda.gov/cder/guidance/4252fnl.htm (accessed May 2004).
31. United States Pharmacopoeia XXXIII, The United States Pharmacopoeia Convention, Rockville, MD, 2003, p. 2439.
32. Shah V.P., Midha K.K., Dighe S., McGilveray I.J., Skelly J.P., Yacobi A., Layloff T., Viswanathan C.T., Cook C.E., McDowall R.D., Pittman K.A., and Spector S. J. Pharm. Sci. 81 (1992) 309
33. Bressolle F., Bromet-Petit M., and Audran M. J. Chromatogr. B 686 (1996) 3
34. Matuszewski B.K., and Constanzer M.L. Anal. Chem. 70 (1998) 882
35. Taylor W.I. J. Am. Chem. Soc. 79 (1957) 3298
36. Jenks C.W. Nat. Prod. Lett. 16 (2002) 71
37. Clivio P., Richard B., Deverre J.R., Sevenet T., Zeches M., and Le Men-Oliver L. Phytochemistry 30 (1991) 3785
38. Mash D.C., Kovera C.A., Pablo J.P., Tyndale R.F., Ervin F.D., Williams I.C., Singleton E.G., and Mayor M. Ann. N.Y. Acad. Sci. 914 (2000) 394